Abstract
Background
Corona virus disease 2019 (COVID-19) has spread around the world since its outbreak, and there is no ascertained effective drug up to now. Lianhua Qingwen (LHQW) has been widely used in China and overseas Chinese, which had some advantages in the treatment of COVID-19.
Objective
To evaluate the efficacy and safety of LHQW for COVID-19 by conducting a systematic review with meta-analysis.
Methods
A comprehensive literature search was conducted in 12 electronic databases from their establishment to October 30, 2021. Note Express 3.2.0 was used for screening of trials, and the data was independently extracted in duplicate by 2 researchers. The risk of bias of randomized controlled trials (RCTs) and retrospective studies were assessed by using the Cochrane collaboration tool and Newcastle Ottawa Scale, respectively, followed by data analysis using RevMan 5.3. The RCTs or retrospective studies to treat COVID-19 using LHQW were included. The intervention measures in the experimental group were LHQW alone or combined with chemical drugs (LCWC), and that in the control group were chemical drugs (CDs). Outcome measures included computed tomography (CT) recovery rate, disappearance rates of primary (fever, cough, fatigue), respiratory, gastrointestinal and other symptoms, exacerbation rate and adverse reaction. Subgroup analysis was conducted according to whether LHQW was combined with CDs and the different treatment methods in the control group.
Results
Nine trials with 1,152 participants with COVID-19 were included. The CT recovery rates of LHQW and LCWC were 1.36 and 1.32 times of CDs, respectively (P<0.05). Compared with CDs, LCWC remarkably increased the disappearance rates of fever, cough, fatigue, expectoration, shortness of breath, and muscle soreness (P<0.05). LHQW also obviously decreased the exacerbation rate, which was 0.45 times of CDs alone (P<0.05). There was no obvious difference between LCWC and CDs in adverse reaction (P>0.05).
Conclusions
LHQW was more suitable for treating COVID-19 patients with obvious expectoration, shortness of breath and muscle soreness. LHQW had advantages in treating COVID-19 with no obvious exacerbation. (PROSPERO No. CRD42021235937)
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci 2020;24:4016–4026.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
National and Provincial Health Commissions. Real time big data report on the epidemic situation of COVID-19 pneumonia. Access on March 24, 2022. Available at https://voice.baidu.com/act/newpneumonia/newpneumonia/?from=osari_aladin_banner.
Wissem H, Nadia BL. COVID-19: main therapeutic options. Tunis Med 2020;98:299–303.
Duan ZP, Jia ZH, Zhang J, Liu S, Chen Y, Liang LC, et al. Natural herbal medicine Lianhuaqingwen Capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J 2011;124:2925–2933.
Yuan B. Chinese medicine, which targets body’s response state, is an effective way to treat epidemic infectious diseases. Chin J Integr Med 2022;28:168–175.
Ji XY, Ma Y, Shi S, Liu SH, Tong L, Lu Cheng, et al. Medication rule analysis of the diagnosis and treatment programs of Chinese medicine for the prevention and treatment of COVID-19 in China. Chin J Integr Med 2022. [Epub ahead of print]
Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020;155:104743.
Liu M, Gao Y, Yuan Y, Yang KL, Shi SZ, Zhang JH, et al. Efficacy and safety of integrated traditional Chinese and Western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res 2020;158:104896.
Zheng SC, Baak JP, Li S, Xiao WK, Ren H, Yang H, et al. Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW. Phytomedicine 2020;79:153336.
National Health Commission of the People’s Republic of China. Guidelines for the diagnosis and treatment of COVID-19 pneumonia. Access on March 4, 2020. Available at http://www.nhc.gov.cn/
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta Anal 2017;5:80–84.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;97:557–560.
Sedgwick P, Marston L. How to read a funnel plot in a meta-analysis. BMJ 2015;351:h4718.
Chen JJ, Zhou YL, Chen FG, Liu X, Chen YL, Wang S. Clinical study on treatment of COVID-19 in convalescent period treated with Lianhua Qingwen Capsule combined with interferon α-2b. Adv Clin Med (Chin) 2020;10:1144–1149.
Cheng DZ, Wang WJ, Li Y, Wu XD, Zhou B, Song QY. Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study. Tianjin J Tradit Chin Med (Chin) 2020;37:509–516.
Fang F, Yang L, Qin SC, Jiao R. Lianhua Qingwen Granule in the treatment of 42 children suspected cases of COVID-19. Chin New Drugs (Chin) 2020;29:2809–2812.
Hu K, Guan WJ, Bi Y, Zhang W, Li LJ, Zhang BL, et al. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial. Phytomedicine 2020;85:153242.
Lv RB, Wang WJ, Li X. Clinical observation on Lianhua Qingwen Granules combined with Western medicine conventional therapy in the treatment of 63 suspected cases of coronavirus disease 2019. J Tradit Chin Med (Chin) 2020;61:655–659.
Xu XH, Dong H, Tu SH, Zhang MM, Liu D, Zhang HQ, et al. Retrospective analysis of Jinye Budu Granule and Lianhua Qinwen Capsule in the treatment of common type COVID-19. Res Integr Tradit Chin West Med (Chin) 2020;12:383–386,389.
Yao KT, Liu MY, Li X, Huang JH, Cai HB. Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. Chin Exp Tradit Med Form (Chin) 2020;26:8–12.
Yu P, Li YZ, Wan SB, Wang Y. Effects of Lianhua Qingwen Granules plus arbidol on treatment of mild corona virus disease-19. Chin Pharm J (Chin) 2020;55:1042–1045.
Yu HY, Ren XH, Qi XX, Zuo Q, Liu D. Efficacy study of arbidol, Qingfei Paidu Decoction, Lianhua Qingwen Capsule and Jinye Baidu Granules in the treatment of mild/moderate COVID-19 in a Fangcang Shelter Hospital. Chin Assoc Chin Med (Chin) 2020;36:2–6.
Hu CY, Liang MM, Gong FF, He B, Zhao DD, Zhang GL. Efficacy of Lianhua Qingwen compared with conventional drugs in the treatment of common pneumonia and COVID-19 pneumonia: a meta-analysis. Evid Based Complement Alternat Med 2020;2020:5157089.
Liu M, Gao Y, Yuan Y, Yang KL, Shi SZ, Tian JH, et al. Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis. Integr Med Res 2021;10:100644.
Zeng MJ, Li LJ, Wu ZQ. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019 (COVID-19): meta-analysis of randomized controlled trials. PLoS One 2020;15:e0238828.
Li GD, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019nCoV). Nat Rev Drug Discov 2020;19:149–150.
Pan WQ, Li RF, Hou YL, Huang JC, Ma QH, Shi YX, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARSCoV2). Pharmacol Res 2020;156:104761.
Wang SH, Liu JF, Zhang YL, Dong Z. Systematic review of efficacy and safety of Lianhua Qingwen Capsules in treatment of viral influenza. Chin J Chin Mater Med (Chin) 2019;44:1503–1508.
Ding Y, Zeng L, Li R, Chen QY, Zhou BX, Chen OL, et al. The Chinese prescription Lianhuaqingwen Capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Alternat Med 2017;17:130.
Author information
Authors and Affiliations
Contributions
Sun XH, Zhang Sh and Tang YP were responsible for the conception and design of the study; Sun XH, Zhang Sh, Yang Z, Chen ZL, Yue SJ and Zhang S conducted the statistical analysis, drew the tables and pictures, and drafted the manuscript; Sun XH, Zhang Sh and Chen ZL retrieved the database, screened the trials, extracted the data, evaluated the methodological quality. All authors critically revised the manuscript and approved the fi nal version.
Corresponding author
Ethics declarations
The authors have no potential conflicts of interest to declare.
Additional information
Supported by the Key Research and Development Program of Shaanxi (No. 2019ZDLSF04-05), Subject Innovation Team of Shaanxi University of Chinese Medicine (No. 2019-YL10)
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Sun, Xh., Zhang, S., Yang, Z. et al. Efficacy and Safety of Lianhua Qingwen for Patients with COVID-19: A Systematic Review and Meta-Analysis. Chin. J. Integr. Med. 28, 650–660 (2022). https://doi.org/10.1007/s11655-022-3578-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11655-022-3578-8